본문으로 건너뛰기
← 뒤로

Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps.

1/5 보강
Vaccines 2026 Vol.14(2)
Retraction 확인
출처

Batbold E, Dashdorj N, Zoulim F, Bartosch B

📝 환자 설명용 한 줄

Persistent infection with hepatitis D virus (HDV), also known as hepatitis delta, is considered the most severe form of chronic viral hepatitis.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Batbold E, Dashdorj N, et al. (2026). Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps.. Vaccines, 14(2). https://doi.org/10.3390/vaccines14020179
MLA Batbold E, et al.. "Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps.." Vaccines, vol. 14, no. 2, 2026.
PMID 41746099 ↗

Abstract

Persistent infection with hepatitis D virus (HDV), also known as hepatitis delta, is considered the most severe form of chronic viral hepatitis. HDV is a defective RNA virus that depends on hepatitis B virus (HBV) for propagation. Despite its global distribution, HDV stays a neglected part of the viral hepatitis agenda, often overlooked in surveillance systems and public health policy. This oversight is particularly concerning given HDV's aggressive clinical course, characterized by more rapid progression to cirrhosis, liver failure, and hepatocellular carcinoma (HCC) compared to HBV mono-infection. Mongolia has the highest incidence and mortality rates of HCC worldwide, with approximately 47% of cases estimated to be attributable to chronic HDV infection. Globally, an estimated 12-25 million people are co-infected with HBV and HDV, although the true prevalence is higher due to insufficient screening and incomplete data collection. Because HDV infection is entirely dependent on HBV, prevention of HBV infection through effective vaccination stands for an indirect yet highly effective strategy to curb HDV transmission. The World Health Organization (WHO), together with the global health community, has established ambitious targets to eliminate viral hepatitis as a public health threat by 2030. However, achieving HDV elimination remains particularly challenging due to limited diagnostic capacity, low awareness, and minimal inclusion of HDV in national hepatitis programs. This review explores the intersection of HDV and HBV, focusing on how expanded and optimized HBV vaccination coverage can serve as a cornerstone of global HDV prevention efforts. We examine epidemiological evidence, scientific rationale, policy developments, and key implementation challenges, with particular attention to high-burden settings such as Mongolia. Finally, we propose strategic recommendations to bridge policy and practice gaps in HDV elimination.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기